Toggle navigation
Toggle navigation
About Inflarx
Leadership Team
Board
Company History
Vision
R&D
About Complement
About C5A
Technology
Pipeline
Clinical Development
Hidradenitis Suppurativa
Shine Study FAQ
ANCA-Associated Vasculitis
Pyoderma Gangraenosum
COVID-19
cSCC
Clinical Trials
Publications & Posters
Investors
Press Releases
Events & Presentations
Financial Information
Share Information
Analyst Coverage
Corporate Governance
Annual/Extraordinary General Meetings
E-mail alerts
Career
Open Positions
Quality Assurance Manager GCP (m/f/d)
04-2011: InflaRx initiates clinical Phase I study
Home
Investors
Press Releases
InflaRx initiates clinical Phase I study
InflaRx initiates Clinical Phase I Study
InflaRx initiates the clinical phase I trial of its lead drug antibody IFX-1.
